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 Abstract 
Several therapeutic properties have been attributed to epigallocatechin gallate 
(EGCG), a phytopharmaceutical polyphenol with antioxidant and antiproliferative activity. 
EGCG is however very prone to oxidation in aqueous solutions which changes its bioactive 
properties. Its loading in nanoparticles has been proposed to reduce its degradation while 
increasing its in vivo efficacy. The aim of this study was to compare the antiproliferative 
effect of EGCG before and after its loading in solid lipid nanoparticles (SLNs), against five 
different cell lines (Caco-2, HepG2, MCF-7, SV-80 and Y-79). EGCG produced 
concentration- and time-dependent antiproliferative effect, with eficacy dependent on the 
cell line. The order of potency was: MCF-7>SV-80>HepG2>Y-79>Caco-2, for 24h 
exposure (MCF-7 IC50=58.60±3.29 µg/mL; Caco-2 IC50>500.00 µg/mL). To the best of our 
knowledge this is the first study reporting EGCG antiproliferative effect in SV-80 and Y-79 
cells. DDAB-SLN physicochemical properties (size 134nm; PI0.179; ZP +28mV) were 
only slightly modified with EGCG loading (EGCG-DDAB-SLN: 144nm; PI0.160; ZP 
+26mV). EGCG loadingin SLN, only slightly increases the EGCG antiproliferative effect 
in MCF-7 and SV-80 cells. SLN exhibited intrinsic toxicity, attributed to the surfactant 
used in its production. From the obtained results, the biocompatibility of blank SLN must 
be also considered when testing the efficacy of loaded phytopharmaceutics. 
 
Keywords: Solid Lipid nanoparticles; Nanoencapsulation; Epigalloacatechin-gallate; Anti-
proliferative effect; Cytotoxicity; Cationic Lipids;   
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 1. Introduction 
Epigallocatechin gallate (EGCG) is the major polyphenol found in green tea (Camellia 
sinensis L.) which has been gaining special interest in food and pharmaceutical industries. 
EGCG has revealed several beneficial health effects, including anti-inflammatory (Cavet et 
al. 2011), anti-carcinogenic (Farabegoli et al. 2011; Santos et al. 2013; Radhakrishnan et al. 
2016; Shin et al. 2016), antioxidant (Cavet et al. 2011; Zhou and Elias 2013), anti-
angiogenic (Yamakawa et al. 2004; Piyaviriyakul et al. 2011), anti-diabetic (Wolfram et al. 
2006; Chen N et al. 2009) and anti-bacterial (Lee S et al. 2017). It has also been reported its 
use as chondroprotective agent as it suppressed the inflammatory response in osteoarthritis 
models (Akhtar and Haqqi 2011; Min S-Y et al. 2015), as well as a cardiovascular protector 
(Wolfram 2007; Oyama et al. 2017) and neuroprotector (Lee JH et al. 2015; Ortiz-López et 
al. 2016). EGCG is the most powerful catechin present in the green tea, regarding the 
chemopreventive and apoptosis inducing molecules (Azam et al. 2004). 
EGCG is known as a powerful antioxidant showing scavenging activity against reactive 
oxygen species (ROS), eliminating radicals (e.g., superoxide anion radical, peroxyl and 
hydroxyl radicals, singlet oxygen, nitric oxide and peroxynitrite, among others (Zhong and 
Shahidi 2012)), as the result of the transfer of hydrogen atom or single-electron transfer 
reactions, involving hydroxyl groups of the B and/or D rings (Min K-j and Kwon 2014). 
Oxidative stress has been considered in many pathological conditions, including cancer (Du 
et al. 2012; Doktorovová et al. 2014), giving EGCG a role as a chemoprotective compound. 
The anti-carcinogenic effects of EGCG are being studied and several works report that this 
polyphenol is able of (i) inhibiting tumorigenesis of the lung (by reducing oxidative DNA 
damage which produces 8-hydroxydeoxyguanosine) (Xu et al. 1992), of oral-digestive tract 
(Du et al. 2012; Santos et al. 2013), and of prostate (Khan et al. 2014); (ii) reducing 
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 vascular endothelial growth factor (VEGF) expression, leading to the inhibition of tumor 
growth and/or angiogenesis (Braicu et al. 2013; Shankar et al. 2013); (iii) inhibiting tumor 
migration and invasion (Lim et al. 2008); and of (iv) inducing cell death through apoptosis 
or to improve lysosomal membrane permeation (Min K-j and Kwon 2014).  
EGCG is a highly unstable molecule especially in water solution, in which it suffers 
oxidation and/or auto-oxidation, epimerization and hydrolysis (Wang et al. 2008; 
Fangueiro, Parra, et al. 2014; Krupkova et al. 2016). These reactions lead to the production 
of other molecules without the equivalent biological or pharmacological interest due to 
poor biological activity (Fangueiro, Parra, et al. 2014). The loading of EGCG has been 
described using lipid nanocapsules (LNC; (Barras et al. 2009)) and solid lipid nanoparticles 
(SLNs) (Fangueiro, Andreani, Fernandes, et al. 2014). The loading of EGCG was carried 
out to ensure EGCG stability in biological media and further improve its bioavailability 
(Barras et al. 2009; Fangueiro, Andreani, Fernandes, et al. 2014; Fangueiro, Parra, et al. 
2014). The nanoencapsulation revealed promising results with excellent encapsulation 
efficiency (> 96%), controlled release of EGCG and safety profile (Fangueiro et al. 2016). 
The use of nanoparticles in drug delivery is a recognised strategy to improve drug’s 
stability and enhance its biological effects. The use of SLN is therefore expected to 
strengthen the well-known effects of EGCG. EGCG seems to exhibit strong anticancer 
effects in vitro, as mentioned above. Thus the main aim of this work was to compare the 
antiproliferative effect of EGCG before and after its loading in SLNs, against five different 
cell lines, including Caco-2 (human epithelial colorectal adenocarcinoma), HepG2 (human 
liver hepatocellular carcinoma), SV-80 (human lung fibroblast), MCF-7 (human breast 
adenocarcinoma) and Y-79 (human retinoblastoma). The assessment of the effect of blank 
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 SLN (without addition of EGCG, with the cationic lipid DDAB as surfactant), was also one 
objective of this work.  
 
2. Materials and methods  
2.1 Materials 
Epigallocatechin gallate (EGCG, 98% purity, MW 458.375 g/mol, pKa 7.59–7.75; CAS 
Number: 989-51-5) and ascorbic acid (AA; MW 176.12 g/mol, CAS Number: 50-81-7) 
were acquired from Sigma-Aldrich (Sintra, Portugal). Dimethyldioctadecylammonium 
bromide (DDAB; MW 630.95 g/mol; CAS Number: 3700-67-2) was acquired from Avanti 
Polar Lipids (Alabama, USA). Softisan
®
100 (S100) was a free sample from Sasol Germany 
GmbH (Witten, Germany), Lipoid
®
 S75, 75% soybean phosphatidylcholine was purchased 
from Lipoid GmbH (Ludwigshafen, Germany), Lutrol
®
F68 or Poloxamer 188 (P188) was a 
free sample from BASF (Ludwigshafen, Germany). Anhydrous glycerol was purchased 
from Acopharma (Barcelona, Spain). Ultra-purified water was obtained from a MiliQ Plus 
system (Millipore, Germany). All reagents were used without further treatment.  
The cell lines Caco-2 (human epithelial colorectal adenocarcinoma), SV-80 (human lung 
fibroblast) and Y-79 (human retina retinoblastoma) were purchased from Cell Lines 
Service (CLS, Eppelheim, Germany), HepG2 (human liver hepatocellular carcinoma) and 
MCF-7 (human breast adenocarcinoma) were from ATCC (ATCC, Rockville, MD). 
Reagents for cell culture were from Gibco (Alfagene, Invitrogene, Portugal). Alamar Blue 
was from Invitrogen Alfagene, Portugal. Other reagents and salts not mentioned were of 
high purity and were acquired from Sigma-Aldrich (Sintra, Portugal).  
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 2.2 Cationic SLN production 
Cationic SLN dispersions were produced based on the multiple emulsion (w/o/w) technique 
as previously described by (Fangueiro, Andreani, Egea, et al. 2014; Fangueiro, Andreani, 
Fernandes, et al. 2014). In brief, the composition of lipid phase (wt%) was: glycerol (37.5), 
Sofitsan S100 (4.5), Lipoid S75 (0.5), cationic lipids (0.5 DDAB) and water. EGCG (15 
mg; to a final 0.075 wt%) and ascorbic acid (1.25 mL; to a final 0.25 wt%) were dissolved 
in ultra-purified water, which was added to the lipid phase at same temperature (5 ºC to 10 
°C above the melting point of lipid S100) and homogenized for 60 s with a sonication 
probe (6 mm diameter) by means of an Ultrasonic processor VCX500 (Sonics, 
Switzerland). A power output with amplitude of 40% was applied. The poloxamer solution 
(1.0 wt%) was added and homogenized for additional 90 s. This pre-emulsion was poured 
in the total volume of poloxamer cooled solution under magnetic stirring for 15 min to 
allow the formation of the SLN (total volume of formulation was 20 mL). Empty SLNs 
followed the same procedure without adding EGCG. The obtained SLNs dispersions were 
used for subsequent studies.  
2.3 Physicochemical characterization 
The physicochemical parameters Z-Ave (mean particle size), PI (polydispersity index) and 
ZP (zeta potential) were determined by dynamic light scattering (DLS, Zetasizer Nano ZS, 
Malvern Instruments, Malvern, UK). All samples were diluted with ultra-purified water to 
suitable concentration and analyzed in triplicate. For the determination of the ZP ultra-
purified water with conductivity adjusted to 50 µS/cm was used. Laser diffraction (LD) was 
performed for particle size analysis by a Mastersizer Hydro 2000 MU (Malvern 
Instruments, Malvern, UK).  
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2.4 Encapsulation efficiency and loading capacity 
Encapsulation efficiency (EE) and loading capacity (LC) of EGCG in SLNs was assessed 
indirectly using filtration/centrifugation followed by quantification of free EGCG (non-
encapsulated) by reverse-phase high-performance liquid chromatography (RP-HPLC), 
using a method previously validated (Fangueiro, Parra, et al. 2014). A volume of 2.0 mL of 
each EGCG-SLNs was placed in centrifugal filter devices Ultracel 100K (100.000 MWCO, 
Amicon Millipore Corporation, Bedford, Massachusetts) and centrifuged at 3000 rpm, 
during 20 min (Sigma 4K10 cen-trifuge, Spain), to separate the lipid and aqueous phase. 
Free EGCG, present in the aqueous phase, was quantified by RP-HPLC, using the same 
method as described in (Fangueiro, Parra, et al. 2014), just after the separation. The 
parameters were quantifyed by applying the following equations:  
𝐸𝐸 (%) = [(𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝐸𝐺𝐶𝐺 − 𝐹𝑟𝑒𝑒 𝐸𝐺𝐶𝐺) (𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝐸𝐺𝐶𝐺)]⁄ × 100 
 
𝐿𝐶 (%) = [(𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝐸𝐺𝐶𝐺 − 𝐹𝑟𝑒𝑒 𝐸𝐺𝐶𝐺) (𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑙𝑖𝑝𝑖𝑑)]⁄ × 100 
 
2.5 Cell culture and viability assay 
Cell culture and maintenance: Caco-2, HepG2 and SV-80 cells were maintained in 
DMEM (Dulbecco's Modified Eagle Medium), MCF-7 in DMEM/F12 (Dulbecco's 
Modified Eagle Medium: Nutrient Mixture F-12) and Y-79 in RPMI-1640 (Roswell Park 
Memorial Institute (RPMI) 1640 medium), supplemented with 10% (v/v) fetal bovine 
serum (FBS), 2 mM L-glutamine, and antibiotics (100 U.mL
−1
 penicillin and 100 μg.mL−1 
of streptomycin) in an atmosphere of 5% CO2 in air at 37 ºC. Culture media was exchanged 
once or twice a week, depending on the cell growth, and passages were done once a week. 
A
ce
pte
d M
an
us
cri
pt
 Cell manipulation for preparations of assays were as described before by us (Severino et al. 
2014).  
Cell manipulation to prepar the assays: Confluent cells were treated with trypsin (except 
Y-79 that does not requires enzymatic treatment as it grows in suspension), a procedure 
identical to that described by us (Severino et al. 2014). After trypsin treatment, cells were 
counted, diluted to a density of 5x10
4
 cells.mL
-1
 and plated in 96-well plates (100 µL per 
well). Cells were left in culture for 24 hours for cell adherence. 
Concerning to Y-79 cells, cells were removed from growing flasks, centrifuged (to 
eliminate the supernatant), re-suspended in FBS-free culture media (gently aspirations with 
the add of a Pasteur pipet permits the desagregation of cells from clusters), counted and, 
after appropriate dilution to 1×10
5 
cells.mL
−1
, cells were seeded in poly-L-lysine pre-coated 
96-well plates (100 µL/well, i.e. 1×10
4 
cells per well). Cells were left in culture for 24 
hours for cell adherence. 
Preparation of test solution and cytotoxicity/viability assay: In this study the different cell 
lines were assayed for cell viability to compare the effect of the following samples: i) 
EGCG in solution, ii) DDAB-SLNs, and iii) DDAB-loaded EGCG SLN. Each formulation 
was tested at four concentrations, calculated as EGCG concentration in solution or in 
formulation. When formulation was deprived of EGCG (blank SLN), identical volumes of 
SLNs formulation were taken and test solutions are presented as “equivalent 
concentrations”. The concentrations used were: 10, 25, 50 and 100 µg.mL−1 (that is, in µM 
of EGCG,: 21.8, 54.5, 109.0 and 218.0, respectively). Test solutions were prepared just 
prior to cell application, using FBS-free culture media into which the required volume of 
respective formulations/solutions was added. To expose the cells to teste solutions, culture 
media was removed and replaced by FBS-free culture media containing the different test 
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 samples. Exposure of 24 h and 48 h was performed, before assaying the cell viability with 
Alamar Blue.  
Cell viability was assayed with Alamar Blue (Invitrogene, Alfagene, Portugal), as 
previously reported (Andreani et al. 2014). Briefly, after 24 h or 48 h of exposure, the 
incubating media was removed and replaced by FBS-free culture media supplemented with 
Alamar Blue 10% (v/v), 100 µL to each well. The absorbance at 570 nm (reduced form) 
and 620 nm (oxidative form) was read 5 h after addition of the Alamar Blue solution. Data 
were analysed by calculating the percentage of Alamar blue reduction (according to the 
manufacturer recommendation and as previously reported (Andreani et al. 2014; Fangueiro, 
Andreani, Egea, et al. 2014; Severino et al. 2014) and expressed as percentage of control 
(untreated cells). 
Calculation of IC50: The IC50 (half maximal inhibitory concentration or the concentration 
that inhibits 50% of cell viability/proliferation) was calculated from each dose-response 
experiment using excel or GraphPad Prism tolls. For each cell line and for each exposure 
time (24 and 48 h), 3 independent experiments were done (each experiment in 
quadriplicate). For each condition, the IC50’ are indicated as the mean ± S.D. of the IC50’ 
calculated for the 3 independent experiments.  
 
2.6. Statistical analysis 
Statistical significance of cell viability data was performed using two-way analysis of 
variance (ANOVA), followed by Tukey multiple comparison test using 95% of confidence, 
i.e. significance of the difference between groups with a p-value < 0.05 was set as 
significant. The multiple t-test using the Bonferroni-Dunn method (95% confidence) was 
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 also used when needed. Data were expressed as the mean value ± standard deviation (mean 
± SD) of n experiments as indicated.  
 
 
3. Results and discussion 
3.1. SLN production and characteristics 
The production of SLN was based on a previous 3
3 
full factorial design (Fangueiro, 
Andreani, Egea, et al. 2014) and EGCG was loaded in SLN prepared by multiple emulsion 
technique (Fangueiro, Andreani, Fernandes, et al. 2014). The analysis by DLS revealed 
particles under 150 nm with a relatively narrow distribution (<0.25) (Table 1). The use of 
cationic lipids, such as DDAB, contributed to the high positive ZP values. This strategy 
was used to promote particles’ stability due to repulsion between positive SLN surface 
charges, reducing particle aggregation and changes in particle size. During storage time, the 
positive charge at particles’ surface, on the other hand, increases interaction with cells as 
these exhibit a negative surface charge. Such enhanced interaction between particles and 
cells would contribute to increase the delivery of the loaded drug but could also interfere 
with the cell membrane stability, leading to cytotoxicity. Indded, a previous work revelead 
that CTAB concentration is an important factor contributing to cell cytotoxicity (Fangueiro, 
Andreani, Egea, et al. 2014). Laser diffraction results also revealed a mean particle size 
within the nanometer range, varying between 115 nm and 120 nm (Table 1). The obtained 
results may anticipate the improvement of SLN cells’ adhesion and their internalization to 
release the drug inside cells. 
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 EGCG has been reported as a valuable natural polyphenol that interferes with several 
biochemical pathways and helps to reduce cancer proliferation (Du et al. 2012; Santos et al. 
2013; Lewandowska et al. 2016). It has been proven that EGCG has high affinity for the 
lipid bilayer of cell membranes, which allows this molecule to enter the cells more easily 
and to exhibited pharmacological effects (Chen L et al. 2002), but the stability of this 
molecule in aqueous solution is poor (Wang et al. 2008), thus stratagies that protect EGCG 
from degradation and preserve its bioactivity are needed. In this work, we have chosen to 
produce SLN using DDAB as cationic surfactant, as a strategy to encapsulate EGCG in 
SLN aiming cell delivery and to protect EGCG from degradation while preserving its 
bioactivity. As shown in Table 1, the loading of EGCG slightly increases the particle size 
(less than 7.5% increase) and sligthy decreases the ZP (about 8 mV).  
Concerning the cell viability, first the anti-proliferative effect of EGCG per se was tested 
(EGCG was dissolved in FBS-free culture media, see methods for details). Five different 
cell lines (Caco-2, HepG2, MCF-7, SV-80 and Y-79) were exposed to different 
concentrations of EGCG (10.0, 25.0, 50.0 and 100.0 µg/mL, that is 21.6, 54.0, 108.0 and 
216.0 µM, respectively, as indicated in Table 2) for 24 and 48 h. In Figure 1, it is observed 
that EGCG dose- and time-dependently reduces cell viability/proliferation, and that the 
dose effect is not identical for the 5 cell lines, while Caco-2 cells were the least affected 
(the most tolerant). MCF-7 cells were those showing lower viability, which is confirmed by 
the IC50 values shown in Table 3. Considering the IC50 values obtained for each cell line 
(Table 3), the order of potency of EGCG in reducing cell viability was: MCF-7 > SV-80 > 
HepG2 > Y-79 > Caco-2, which is identical for 24 h as for 48 h exposure. We also can 
observe that the effect of exposure time is more evident for Caco-2 and for Y-79 cells 
(Table 3 and Figure 1) and has a lower effect in MCF-7 cells. Indeed, in Caco-2 cells 
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 (Figure 1A) the viability after 48 h exposure was lower than at 24 h, for all tested 
concentrations (p<0.05) while for MCF-7 cells (Figure 1C) statistically significant 
differences between time were only observed at the highest tested concentration (p<0.05). 
The antiproliferative effect of EGCG has been tested in several cell lines. There is a general 
concensus with the fact that cell lines having p53 mutation are more resistant to many 
chemotherapeutic agents (Du et al. 2012; He et al. 2017), as these cells may have enhanced 
drug efflux and metabolism, activated mechanisms that promote survival, inhibited 
apoptosis, among other characteristics (He et al. 2017). Among the five cell lines tested, 
Caco-2 has mutated p53 while HepG2, MCF-7 are p53 wild type; concerning Y-79 data 
indicate a mutation in RB and p53 gene (Laurie et al. 2006) and SV-80 expresses two 
isoforms of p53 (Harris et al. 1986). In this study the cells with p53 mutation were the most 
resistant against the EGCG chemotherapeutic effect. Concerning EGCG effect in other 
colorectal cancer cell lines, Du et al., (2012) used HCT-116 (p53 wild type) and SW-480 
(with a p53 mutation) and observed a stronger effect in HCT-116 that in SW-480, which is 
in line with the fact that p53 may play an important role in cell proliferation and in the 
modulation of polyphenols effects. Other authors also observed cell viability reduction 
upon EGCG exposure using Caco-2 (showing IC50 values lower than those reported in our 
work (Kang 2015)), MCF-7 (10 µM produced 70% viability (Kang 2015)), HepG2 (IC50 at 
48 h exposure was 74.7 µg/mL (Shen et al. 2014) a value similar to that report by us) and to 
the best of our knowledge this is the first report testing different EGCG concentrations and 
incubation times in SV-80 and Y-79 cells (Figure 1D and Figure 1E, respectively). 
As all the IC50’ are above 30 µg/mL (i.e. 65.4 µM), the encapsulation in SLN should 
increase biological efficacy while reducing EGCG degradation, thus we would expect 
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 lower IC50 values for encapsulated EGCG. EGCG was successfully encapsulated in SLN 
formulation, using DDAB as cationic lipid (Fangueiro, Andreani, Fernandes, et al. 2014), 
with an encapsulation efficiency (EE) of about 97 % (i.e. 96.86 ± 1.88% (Fangueiro, 
Andreani, Fernandes, et al. 2014)) and a LC of about 15%. In a previous study, we reported 
that CTAB concentrations compromise Y-79 cell viability at concentrations above 0.5% 
(wt%) (Fangueiro, Andreani, Egea, et al. 2014). CTAB concentration is however relevant 
to particle size which decreases as CTAB concentration increases (239.5 ± 0.61 nm to 
144.7 ± 1.61 nm, at 0.25 and 1.0% (wt%), respectively) and to grant SLN high surface 
charge which increases with the concentration, from +24 mV, at 0.25%, to +48 mV, at 
1.0% (wt% in formulation), which is needed to maintain size stability and to favour cellular 
interaction (Fangueiro, Andreani, Egea, et al. 2014). EGCG-DDAB-SLN were prepared, 
characterized (Table 1 and (Fangueiro, Andreani, Fernandes, et al. 2014)) and applied to 
the five cell lines. The test solutions were prepared by diluting the SLN volumes, in FBS-
free culture media, yielding 10, 25, 50 and 100 µg/mL of EGCG.  
Figure 2 shows the results obtained for cell viability after 24 h exposure to EGCG-DDAB-
SLN (comparing with EGCG and blank SLN, DDAB-SLN, at 24 h) and Table 3 shows the 
calculated IC50, for 24 and 48 h exposure. As shown in Figure 2 and Table 3, DDAB-SLN 
exhibited lower dose-dependent toxicity, being the cell viability above 90% of control (for 
all tested cell lines) at 165 µg/mL DDAB (or, 261.51 µM; i.e., at 25 µg/mL of EGCG 
equivalent; Table 2) and above 50% for twice this concentration. Also, the effect of DDAB-
SLN was shown to be influenced by the cell line, showing a order of potency (at 24 h 
exposure): HepG2 > SV-80 > Y-79 > Caco-2 > MCF-7 (Table 3). Loading of EGCG in 
DDAB-SLN, enhanced the EGCG anti-proliferative effect only in SV-80 cells (Figure 2D), 
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 while in the other cell lines the IC50 produced by EGCG-DDAB-SLN was comparable to 
the EGCG and to the blank SLN (Figure 2). In HepG2, MCF-7 and Caco-2 cell lines the 
encapsulated EGCG (EGCG-DDAB-SLN) protected the cells against toxicity, as it is lower 
than that of blank SLN, thus EGCG should be acting as an antioxidant rather than as 
antiproliferative agent. From the results obtained in this work, one should also bear in mind 
that the components of SLN may also exhibit some level of toxicity as the loaded 
phytochemicals/drugs, as that, if not targeted adequately, the site-unspecific damage might 
be higher then the desired therapeutic effect. Thus, convenient control assays should always 
be performed and demonstrated. 
 
4. Conclusions 
EGCG exhibits anti-proliferative effect which is time- and concentration dependent and 
also depends on the tested cell line (order of potency: MCF-7 > SV-80 > HepG2 > Y-79 > 
Caco-2, for 24 h exposure). As has been reported, encapsulation of EGCG improves its 
stability and should improve its efficacy as anti-proliferative agent, which was only 
observed for SV-80 cells. Production of SLN requires the use of surfactants both for 
stereochemical and electrostatic stabilization. Surfactants surrounding the particles may 
also play a relevant role in the as cell internalization of particles/drug.  Some surfactants 
may also damage cells by direct interfering with cell membrane integrity. In this work we 
have shown that DDAB is tolerated by cells in concentrations that are compatible to SLN 
production. One must also bear in mind that these cells have no protection against 
membrane damaging agents which can be translated in a higher toxicity than the effect that 
may be observed in vivo. 
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Figure captions: 
Figure 1. Anti-proliferative effect of EGCG in Caco-2 (A), HepG2 (B), MCF-7 (C), SV-80 
(D) and Y-79 (E) cells. Cells were exposed to different concentrations of EGCG (10, 25, 50 
and 100 µg/mL (see methods for details)) for 24 and 48 h (as indicated). Cell viability was 
assessed with alamar blue indicator and data are presented as % of control (non-exposed 
cells), as mean ± SD (n = 3 independent experiments, see methods). Statistical significance 
(p<0.05) between control and different concentrations (at same incubation time) is 
indicated with an asterisk (*) and between different exposure times at same concentration is 
indicated by a delta (Δ).  
 
Figure 2. Dose-dependent effect of DDAB-SLN (); EGCG (▼), EGCG-DDAB-SLN (■) 
in Caco-2 (A), HepG2 (B), MCF-7 (C), SV-80 (D) and Y-79 (E) cell viability, at 24 h 
exposure. Cells were exposed to different concentrations of EGCG and to concentrations of 
EGCG-DDAB-SLN and blank SLN (DDAB-SLN) that give the same amount of EGCG, as 
denoted (10, 25, 50 and 100 µg/mL (see methods for details)), for 24 h. Cell viability is 
presented as % of control (non-exposed cells), as mean ± SD (n = 3 independent 
experiments, see methods). For each condition, statistical significance (p<0.05) between 
control and different concentrations is indicated with an asterisk (*, set above the line for 
DDAB-SLNs and below the line for EGCG-DDAB-SLNs; for EGCG please see Figure 1). 
Statistical significance (p<0.05) between the effect of EGCG in solution and encapsulated 
(EGCG-DDAB-SLNs), at same concentration, is indicated by a delta (Δ).  
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 Table captions: 
Table 1. Analysis by dynamic light scattering (DLS) indicating the mean particle size (Z-
Ave), polydispersity index (PI) and zeta potential (ZP) and by laser diffraction (LD) of 
Lipid Nanoparticles dispersions. The results are expressed as mean ± S.D. (n = 3).  
 
Table 2. Composition of test solutions regarding to EGCG and DDAB, in µg/mL and µM. 
The molecular weight (g/mol) of EGCG and DDAB is 458.37and 630.95, respectively. The 
wt% (g/100 mL) of each compound in formulation was 0.075and 0.5, respectively, as 
indicated in methods. 
 
Table 3. Values of IC50 calculated for each cell line exposed to EGCG, EGCG-DDAB-
SLN, and DDAB-SLN for 24 or 48 h (as indicated). Values represent the mean ± S.D., as 
indicated in methods. 
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Table 1. Analysis by dynamic light scattering (DLS) indicating the mean particle size (Z-
Ave), polydispersity index (PI) and zeta potential (ZP) and by laser diffraction (LD) of 
Solid lipid Nanoparticle dispersions. The results are expressed as mean ± S.D. (n = 3).  
Formulation 
DLS LD 
Z-Ave (nm) PI ZP (mV) d50 (nm) 
DDAB-SLN 134.2 ± 1.120 0.179 ± 0.067 +28.20 ± 2.290 119.8 ± 0.01 
EGCG DDAB-SLN 143.7 ± 0.450 0.160 ± 0.015 +25.70 ± 1.420 115.0 ± 0.00 
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 Table 2. Composition of test solutions regarding to EGCG and DDAB, in µg/mL and µM. 
The molecular weight (g/mol) of EGCG and DDAB is 458.37and 630.95, respectively. The 
wt% (g/100 mL) of each compound in formulation was 0.075and 0.5, respectively, as 
indicated in methods. 
  Test solution concentration (EGCG equivalent (µg/mL)) 
Compound Concentration 10 25 50 100 
EGCG (*) µg/mL 10.00 25.00 50.00 100.00 
 µM 21.60 54.00 108.00 216.00 
DDAB (*) µg/mL 66.00 165.00 330.00 660.00 
 µM 104.60 261.51 523.02 1046.04 
(*) Test solutions are identified regarding these compounds (see figure legends). 
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 Table 3. Values of IC50 calculated for each cell line exposed to EGCG, EGCG-DDAB-
SLN, DDAB-SLN for 24 or 48 h (as indicated). Values represent the mean ± S.D., as 
indicated in methods. 
  IC50 (µg/mL)* 
Cell line Time EGCG EGCG-DDAB-SLN  DDAB-SLN 
Caco-2 
24 h > 500.00 482.54 ± 41.46 189.09 ± 29.41 
48 h 298.61 ± 2.39 412.99 ± 41.98 168.06 ± 16.36 
HepG2 
24 h 83.47 ± 7.53 91.17 ± 14.87 77.31 ± 5.47 
48 h 82.23 ± 4.31 114.68 ± 36.17 52.05 ± 1.60 
MCF-7 
24 h 58.60 ± 3.29 145.15 ± 45.93 233.87 ± 31.60 
48 h 35.67 ± 3.34 127.72 ± 20.39 176.38 ± 18.93 
SV-80 
24 h 62.13 ± 2.69 91.67 ± 6.007 106.67 ± 4.98 
48 h 46.12 ± 1.41 31.35 ± 3.15 43.04 ± 5.17 
Y-79 
24 h 133.33 ± 10.56 181.59 ± 30.29 153.83 ± 11.97 
48 h 57.41 ± 8.45 85.09 ± 8.92 81.85 ± 3.18 
* Values are expressed as the amount of EGCG equivalent in formulation. 
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